Projects overview

Sort by

Toggle all information

PharmaLedger | PharmaLedger

01-01-2020

-

31-12-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-02 Blockchain Enabled Healthcare

EU-PEARL | EU Patient- cEntric clinicAl tRial pLatform

01-11-2019

-

30-04-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-01 Integrated research platforms enabling patient-centric drug development

imSAVAR | Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies

01-12-2019

-

30-11-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-04 Emerging translational safety technologies and tools for interrogating human immuno-biology

COMBINE | Collaboration for Prevention and Treatment of MDR Bacterial Infections

01-11-2019

-

31-10-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-07 AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries

ImmUniverse | Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

01-01-2020

-

30-06-2026

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-03 Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases

IDEA-FAST | Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases

01-11-2019

-

30-04-2026

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-06 Digital endpoints in neurodegenerative and immune-mediated diseases

ERA4TB | EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

01-01-2020

-

31-12-2026

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-08 AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
Powered by Chris Decubber BV